Updates are available Correction dated 2021-10-18
Click to view Correction: https://doi.org/10.1038/s41587-021-01081-5
-
Authors
Shah, Nisarg J. http://orcid.org/0000-0003-1727-5732
Mao, Angelo S.
Shih, Ting-Yu
Kerr, Matthew D.
Sharda, Azeem
Raimondo, Theresa M.
Weaver, James C.
Vrbanac, Vladimir D.
Deruaz, Maud http://orcid.org/0000-0001-9294-070X
Tager, Andrew M.
Mooney, David J. http://orcid.org/0000-0001-6299-1194
Scadden, David T.
- License Information
-
More Information
Article History
Received: 27 November 2017
Accepted: 21 December 2018
First Online: 11 February 2019
Change Date: 18 October 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41587-021-01081-5
Competing interests
: Magenta Therapeutics, equity and consulting: D.T.S.; Agios Pharmaceuticals, director, equity: D.T.S.; Fate Therapeutics, equity and consulting: D.T.S.; Clear Creek Bio, director, equity and consulting: D.T.S.; FOG Pharma, consulting: D.T.S.; Red Oak Medicines, director, equity, consulting: D.T.S.; Lifevaultbio, director, equity: D.T.S.; Bone Therapeutics, consulting: D.T.S.; Novartis, sponsored research: D.T.S. and D.J.M.; Agnovos, consulting: D.J.M.; Amgen, sponsored research: D.J.M.; Samyang Corp., consulting: D.J.M.; Decibel, sponsored research: D.J.M.; Merck, sponsored research: D.J.M.; Immulus, equity: D.J.M.; Inventors, patent applications (PCT/US2017/016729): N.J.S., A.S.M., T.-Y.S., D.J.M. and D.T.S.
